Aequus Pharmaceuticals (AQS) Stock Price, News & Analysis

Company Overview

Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: C$0.01 to C$0.01
• 50-Day Range: C$0.01 to C$0.01
• 52-Week Range: C$0.01 to C$0.04
• Volume: 100,000 shs
• Average Volume: 162,442 shs
• Market Capitalization: C$663.15 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: CVE:AQS
• CIK: N/A
• Web: www.aequuspharma.ca
• Phone: +1-604-3367906
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$2.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,569.60%
• Return on Assets: -178.79%

Debt

• Debt-to-Equity Ratio: 138.88
• Current Ratio: 0.07
• Quick Ratio: 0.46

Sales & Book Value

• Annual Sales: C$1.17 million
• Price / Sales: 0.57
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 5.00
• Book Value: C($0.04) per share
• Price / Book: -0.13

Miscellaneous

• Outstanding Shares: 132,630,000
• Free Float: N/A
• Market Cap: C$663.15 thousand
• Optionable: Not Optionable
• Beta: -0.02